ArticleJournal of translational medicine2019
Preparing for cell culture scale-out: establishing parity of bioreactor- and flask-expanded mesenchymal stromal cell cultures.
Article in Journal of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- From microtissues to macro solutions - The future of scalable and automated cartilage tissue engineering.Journal of orthopaedic translation · 2026Review
- Genomic Monitoring and Engineering Stable and Safe Immortalized Cell Platforms for Industrial Cellular Agriculture.Foods (Basel, Switzerland) · 2026Review
- Automated and scalable expansion of human liver organoids for translational applications.Journal of translational medicine · 2026Article
- Can cell-cultured meat from stem cells pave the way for sustainable alternative protein?Current research in food science · 2025Article
- Comparison of Cost and Potency of Human Mesenchymal Stromal Cell Conditioned Medium Derived from 2- and 3-Dimensional Cultures.Bioengineering (Basel, Switzerland) · 2023Article
- Neurodifferentiation and Neuroprotection Potential of Mesenchymal Stromal Cell-Derived Secretome Produced in Different Dynamic Systems.Biomedicines · 2023Article
- A passage-dependent network for estimating theFrontiers in cell and developmental biology · 2023Article
- An optimized procedure for preparation of conditioned medium from Wharton's jelly mesenchymal stromal cells isolated from umbilical cord.Frontiers in molecular biosciences · 2023Article
- Translating stem cell research into development of cellular drugs-a perspective from manufacture of stem cell products and CMC considerations.Cell proliferation · 2022Review
- Towards Physiologic Culture Approaches to Improve Standard Cultivation of Mesenchymal Stem Cells.Cells · 2021Review
- Agitation in a Microcarrier-based Spinner Flask Bioreactor Modulates Homeostasis of Human Mesenchymal Stem Cells.Biochemical engineering journal · 2021Article
- Numerical Methods for the Design and Description of In Vitro Expansion Processes of Human Mesenchymal Stem Cells.Advances in biochemical engineering/biotechnology · 2021Review
- Automated Large-Scale Production of Paclitaxel Loaded Mesenchymal Stromal Cells for Cell Therapy Applications.Pharmaceutics · 2020Article
- Biological Considerations in Scaling Up Therapeutic Cell Manufacturing.Frontiers in pharmacology · 2020Review
- Limited Potential or Unfavorable Manipulations? Strategies Toward Efficient Mesenchymal Stem/Stromal Cell Applications.Frontiers in cell and developmental biology · 2020Review
- Influence of Microenvironment on Mesenchymal Stem Cell Therapeutic Potency: From Planar Culture to Microcarriers.Frontiers in bioengineering and biotechnology · 2020Review
- Mesenchymal Stem/Progenitor Cells: The Prospect of Human Clinical Translation.Stem cells international · 2020Review
- Multi-Parameter Analysis of Biobanked Human Bone Marrow Stromal Cells Shows Little Influence for Donor Age and Mild Comorbidities on Phenotypic and Functional Properties.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCell-based therapies have the potential to become treatment options for many diseases, but efficient scale-out of these therapies has proven to be a major hurdle. Bioreactors can be used to overcome this hurdle, but changing the culture method can introduce unwanted changes to the cell product. Therefore, it is important to establish parity between products generated using traditional methods versus those generated using a bioreactor.
methodsMesenchymal stromal cells (MSCs) are cultured in parallel using either traditional culture flasks, spinner vessels or a new bioreactor system. To investigate parity between the cells obtained from different methods, harvested cells are compared in terms of yield, phenotype and functionality.
resultsBioreactor-based expansion yielded high cell numbers (222-510 million cells). Highest cell expansion was observed upon culture in flasks [average 5.0 population doublings (PDL)], followed by bioreactor (4.0 PDL) and spinner flasks (3.3 PDL). Flow cytometry confirmed MSC identity (CD73
conclusionsThe new bioreactor technology can be used to culture large amounts of cells with characteristics equivalent to those cultured using traditional, flask based, methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.